Condition: Locally Advanced Vulvar Carcinoma · Squamous Cell Carcinoma of the Vulva · Sponsor: The Netherlands Cancer Institute
A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for six weeks) and experimental treatment (NACT; consisting of carboplatin and paclitaxel in a 3-weekly scheme) will be compared in 98 patients with LAVC, registered from eight national medical centres.
This description comes directly from the study's public registry record.
Frederic Amant, Prof. · 0031205129111 · f.amant@nki.nl
Always discuss trial participation with your own doctor first.
| NKI-AVL | Amsterdam, Netherlands | Recruiting |
| LUMC | Leiden, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05905315